Updated:
Senmed Medical Ventures
Senmed Medical Ventures, led by ex-Goldman and J.P. Morgan analyst Franklin Berger, invests in digital health and medical devices from New York.
Senmed Medical Ventures
Senmed Medical Ventures formed in 2016 under Franklin M. Berger, a veteran healthcare analyst who spent over 20 years on Wall Street covering biotechnology at firms including J.P. Morgan, Goldman Sachs, and Salomon Smith Barney before launching his own advisory and investment platform. The firm operates from New York, drawing on Berger's deep ties to clinical-stage and growth-equity healthcare companies cultivated across decades of institutional research. The portfolio targets digital health, healthcare services, and medical device companies, favoring regulatory-stage therapeutics platforms and capital-efficient service models. The firm participates in direct equity and advisory engagements, blending strategic consulting with minority-equity positions in early-to-growth-stage ventures. Publicly confirmed holdings include BioSig Technologies, where Berger has served as a strategic advisor to the board, and other privately held precision-medicine and remote-monitoring assets. The geographic focus is predominantly North America, with select exposure to Israeli medtech, a market Berger has covered extensively since the early 2000s. Team size, total committed capital, and aggregate deployment figures are not publicly disclosed. The firm maintains a lean model — often embedding advisory work alongside capital — rather than a multi-tiered fund structure. There is no publicly identified affiliated foundation or co-investor club. In recent years, Berger's public commentary has centered on the convergence of AI-driven diagnostics and value-based care reimbursement tailwinds. Senmed's structural differentiator is its operator-as-investor model: the firm's principal provides strategic advisory services to portfolio companies, blending an institutional research pedigree with hands-on board-level guidance. This hybrid posture — part consulting, part principal investing — is unusual in a sector where venture firms typically staff separate venture partners for portfolio support.
General information
Firm type
Asset Manager
Year founded
2016
AUM
Undisclosed
Location
Region
North America
Country
United States
City
New York
Corporate office
New York, NY, United States
Principals
Franklin M. Berger
Managing Partner
Sector focus
Frequently asked questions
Who runs investment decisions at Senmed Medical Ventures?
Investment decisions are led by Managing Partner Franklin M. Berger. Berger brings over two decades of sell-side biotech research experience to the role, having held senior analyst positions at J.P. Morgan, Goldman Sachs, and Salomon Smith Barney before founding the firm in 2016. The firm operates without a publicly named investment committee beyond Berger.
What investment stages does Senmed Medical Ventures typically target?
The firm typically targets early-stage to growth-equity healthcare companies that have reached clinical or regulatory inflection points. Berger's background in covering publicly traded biotech informs a preference for companies with near-term catalysts. The firm has engaged with pre-revenue and commercial-stage companies alike, often entering through advisory relationships that later convert to equity.
Does Senmed Medical Ventures participate in fund commitments or only direct deals?
Available evidence points to direct investments and advisory engagements rather than fund-of-fund commitments. The firm has not publicly disclosed any limited partner positions in third-party venture funds. Its model appears built around concentrated, relationship-driven principal investments.
Which sectors does Senmed Medical Ventures explicitly avoid?
The firm does not publish a formal exclusion list. However, its historical positioning in digital health, medical devices, and services — rather than pure-play drug discovery — suggests a deliberate focus on capital-light healthcare business models. There is no public record of investments in provider networks or hospital systems.
How is Senmed Medical Ventures structured relative to Franklin Berger's advisory work?
The firm operates as an integrated advisory-and-investment platform. Berger provides strategic consulting to portfolio companies — often taking formal advisory or board roles — and deploys capital through the same entity. This structure differs from the typical venture capital firm, where advisory and investment functions are more clearly separated.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: